Comparison of Potassium Binders in the ER
Who is this study for? Patients with Acute Hyperkalemia
Status: Terminated
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
Compare efficacy of 3 oral potassium binders (cation exchange resins) on lowering blood potassium, in hospital patients with acute hyperkalemia.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Plasma potassium \> 5.5 mEq/L
• Age ≥18 years
• Patient able to provide written informed consent
Locations
United States
California
University of California, Irvine Medical Center
Orange
Time Frame
Start Date: 2020-10-20
Completion Date: 2025-01-31
Participants
Target number of participants: 37
Treatments
Experimental: Polyethylene glycol 3350 (MiraLax)
Participants will be randomized to one of four study arms. They will receive one dose of the study drug.~One study arm is the nonspecific laxative MiraLax (one dose of 17g). Since constipation can contribute to hyperkalemia, this arm will study the effect of treating constipation instead of direct cation exchange for potassium in the gut.
Experimental: Sodium polystyrene sulfonate (Kayexalate)
Participants will be randomized to one of four study arms. They will receive one dose of the study drug.~The potassium binder drugs of interest include sodium polystyrene sulfonate (one dose of 30g), patiromer (one dose of 25.2g), and sodium zirconium cyclosilicate (one dose of 15g).
Experimental: Patiromer (Veltassa)
Participants will be randomized to one of four study arms. They will receive one dose of the study drug.~The potassium binder drugs of interest include sodium polystyrene sulfonate (one dose of 30g), patiromer (one dose of 25.2g), and sodium zirconium cyclosilicate (one dose of 15g).
Experimental: Sodium zirconium cyclosilicate (Lokelma)
Participants will be randomized to one of four study arms. They will receive one dose of the study drug.~The potassium binder drugs of interest include sodium polystyrene sulfonate (one dose of 30g), patiromer (one dose of 25.2g), and sodium zirconium cyclosilicate (one dose of 15g).
Related Therapeutic Areas
Sponsors
Leads: University of California, Irvine